Thyrotropin-releasing hormone-degrading ectoenzyme (TRHDE)

Thyrotropin-releasing hormone-degrading ectoenzyme (TRHDE) is a zinc-dependent metallopeptidase of the M1 aminopeptidase family with a highly specific activity for hydrolyzing thyrotropin-releasing hormone (TRH) and a few related tripeptides. It is a type II cell surface ectoenzyme, expressed predominantly in the brain (notably by β₂-tanycytes in the hypothalamus), anterior pituitary, and peripheral tissues such as the liver. TRHDE regulates the duration and intensity of TRH's effects by inactivating extracellular TRH, thereby finely controlling the hypothalamic-pituitary-thyroid axis and possibly other central neuroregulatory functions. Its narrow substrate specificity and tissue expression profile identify it as a promising therapeutic target for the modulation of TRH signaling pathways; inhibitors can potentiate TRH-mediated effects, while risk/benefit for CNS or metabolic disorders remains to be fully established[1][3].

Other names

Pyroglutamyl-peptidase IITRH-DETRH-degrading ectoenzymeThyroliberinaseTRH-specific aminopeptidasePAP-IIPGPEP2Thyrotropin-releasing hormone degrading enzymeTRHDE

Inhibition of TRHDE prolongs TRH activity by preventing its extracellular degradation, Potential dual action as both TRH receptor agonist and TRHDE inhibitor (for some analogs), Enhancement of TRH-mediated neuroprotective or metabolic effects